NCT00411567已完成1 期
An Open Label Study to Assess the Utility of Measuring Markers of Inflammation, to Detect Transition From Optimal to Sub-Optimal Inhaled Corticosteroid Therapy in Moderate-Severe Bronchial Asthma
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Novartis
- 入组人数
- 26
- 试验地点
- 2
- 主要终点
- Change in inflammatory parameters in response to a decrease in ICS compared to no change in therapy after 2 and 4 weeks
研究概览
简要总结
The purpose of this study is to investigate/assess the treatment of moderate to severe asthmatics with inhaled corticosteroid.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and/or female moderate to severe asthmatic patients, from 18-75 years of age.
- •Moderate to severe asthma, according to the GINA guidelines, for at least one year with no exacerbations requiring hospitalization and/or oral steroids within the previous three months.
- •No concomitant lung disease or significant medical conditions
- •Fluticasone propionate 500mcg daily or greater, or equivalent (Mometsaone 800 mcg, triamcinolone 2000 mcg, Flunisolide 2000 mcg, Budesonide DPI 800 mcg, Beclomathasone HFA 500 mcg, Beclomethasone CFC 1000 mcg, Forced expiratory volume in 1 second (FEV1) at screening will be ≥ 70% of the normal predicted.
- •Evidence of asthma, demonstrated by one of the following: Historical evidence confirmed by their treating physician or Demonstration of ≥ 12% reversibility of FEV1 using a standard dose of salbutamol (up to 400 µg) within 30 minutes.
- •Female subjects of child bearing potential must be using two forms of contraception or postmenopausal women must have no regular menstrual bleeding for at least 2 years prior to inclusion.
- •Body Mass Index between 18 and
- •Body weight should be less than 100 kg.
排除标准
- •Concomitant medications: Except for short- and long-acting β-agonists and medication which may be required to treat adverse events, all other medications, other than study drug should be avoided from screening until all of the study completion evaluations have been conducted. Paracetamol is acceptable.
- •Medical conditions: history of clinically significant drug allergy; any significant medical condition. For example, a history of any pulmonary disorder other than asthma.
- •Any surgical or medical condition which might significantly alter the distribution, metabolism or excretion of the drug.
- •Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulation.
- •Donation or loss of 400 mL or more of blood within 8 weeks prior to dosing or longer if required by local regulation.
- •Significant illness within the two weeks prior to dosing.
- •A past personal or close family medical history of clinically significant cardiac abnormalities
- •History of history of fainting, orthostatic hypotension, sinus arrhythmia, etc.
- •A known hypersensitivity to Fluticasone propionate or drugs similar to Fluticasone propionate.
- •History of immunocompromise, including a positive HIV test result.
- •A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.
- •History of drug or alcohol abuse within the 12 months prior to dosing
- •Other protocol-defined inclusion/exclusion criteria may apply
结局指标
主要结局
Change in inflammatory parameters in response to a decrease in ICS compared to no change in therapy after 2 and 4 weeks
次要结局
- Parameter/combination of parameters most sensitive to the ICS reduction
- Collection of relative data to assess sample size calculations for subsequent studies
研究者
研究点 (2)
Loading locations...
相似试验
已完成
4 期
An Open-label Study to Evaluate Correct Use and Ease of Use of the ELLIPTA DPI in Pediatric Subjects With AsthmaAsthmaNCT03478657GlaxoSmithKline222
已完成
3 期
Trial to Compare the Safety, Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus in Children With AsthmaAsthmaNCT00192257MedImmune LLC2,229
已完成
4 期
A Comparative Study To Determine If Motivating Asthma Education (Compliance Enhancement) Has An Effect On Asthma ControlAsthmaNCT00351143GlaxoSmithKline274
已完成
4 期
Evaluation Of Patient Satisfaction Of Metered Dose Inhaler (MDI) With Counter In Asthmatics And Chronic Obstructive Pulmonary Disease Patients (COPD).AsthmaNCT00404261GlaxoSmithKline132
已完成
3 期
Study of an Approved Drug in Patients With Asthma (0476-289)(COMPLETED)AsthmaNCT00092144Organon and Co500